Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

British journal of cancer - 26 Aug 2014

Kriege M, Hollestelle A, Jager A, Huijts P E A, Berns E M, Sieuwerts A M, Meijer-van Gelder M E, Collée J M, Devilee P, Hooning M J, Martens J W M, Seynaeve C

Abstract excerpt

BACKGROUND: We assessed the sensitivity to adjuvant chemotherapy in cell cycle checkpoint kinase 2 (CHEK2) vs non-CHEK2 breast cancer patients by comparing the contralateral breast cancer incidence and distant disease-free and breast cancer-specific survival between both groups, stratified for adjuvant chemotherapy. METHODS: One Dutch hereditary non-BRCA1/2 breast cancer patient cohort (n=1220) and two Dutch...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Disease-Free Survival

Share to CHEK2 gene

Share to Genetic Predisposition to Disease

Share to Genotype

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 24918820
DOI: 10.1038/bjc.2014.306
PMCID: PMC4150261

Genes

CHEK2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.PMID 24918820Read ↗

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.Semantic proximity Read ↗

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.Semantic proximity Read ↗

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.Semantic proximity Read ↗

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalSemantic proximity Read ↗

Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.Semantic proximity Read ↗

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.Semantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.Semantic proximity Read ↗

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.Semantic proximity Read ↗

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.Semantic proximity Read ↗

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.